Severe Neutropenia Secondary to Ocrelizumab: Risk Factors (P8-1.015)
To analyze the incidence of severe neutropenia (SN) in multiple sclerosis (MS) patients treated with Ocrelizumab (MS-OC) and identify potential risk factors.
Authors
- Ester Carreón Guarnizo (ORCID: https://orcid.org/0000-0002-8413-0536)
- Carla Giménez (ORCID: https://orcid.org/0009-0002-0191-5408)
- Fabián Hernández (ORCID: https://orcid.org/0000-0002-4409-5094)
- Manel Perelló (ORCID: https://orcid.org/0000-0003-1859-5279)
- David Vidal Mena
- J Cabeza Barrera
- José Antonio Pérez Vicente
- Juan Sanchís
- Blanca Gómez Gozálvez
Institutions
- Santa Lucía University General Hospital (ES)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211332
- Citations
- 1
- Primary Topic
- Blood disorders and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.82